Cancer evolves through the accumulation of mutations, but the order in which mutations occur is poorly understood. Inference of a temporal ordering on the level of genes is challenging because clinically and histologically identical tumors often have few mutated genes in common. This heterogeneity may at least in part be due to mutations in different genes having similar phenotypic effects by acting in the same functional pathway. We estimate the constraints on the order in which alterations accumulate during cancer progression from cross-sectional mutation data using a probabilistic graphical model termed Hidden Conjunctive Bayesian Network (H-CBN). The possible orders are analyzed on the level of genes and, after mapping genes to functional pathways, also on the pathway level. We find stronger evidence for pathway order constraints than for gene order constraints, indicating that temporal ordering results from selective pressure acting at the pathway level. The accumulation of changes in core pathways differs among cancer types, yet a common feature is that progression appears to begin with mutations in genes that regulate apoptosis pathways and to conclude with mutations in genes involved in invasion pathways. H-CBN models provide a quantitative and intuitive model of tumorigenesis showing that the genetic events can be linked to the phenotypic progression on the level of pathways.
References
[1]
Merlo LMF, Pepper JW, Reid BJ, Maley CC (2006) Cancer as an evolutionary and ecological process. Nat Rev Cancer 6: 924–935.
[2]
Michor F, Iwasa Y, Nowak MA (2004) Dynamics of cancer progression. Nat Rev Cancer 4: 197–205.
[3]
Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194: 23–28.
[4]
Futreal PA, Coin L, Marshall M, Down T, Hubbard T, et al. (2004) A census of human cancer genes. Nat Rev Cancer 4: 177–183.
[5]
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57–70.
[6]
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646–674.
[7]
Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10: 789–799.
[8]
Jones S, Zhang X, Parsons DW, Lin JC-H, Leary RJ, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801–1806.
[9]
Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807–1812.
[10]
Wood LD, Parsons DW, Jones S, Lin J, Sj？blom T, et al. (2007) The genomic landscapes of human breast and colorectal cancers. Science 318: 1108–1113.
[11]
Moolgavkar SH, Luebeck EG (1992) Multistage carcinogenesis: population-based model for colon cancer. J Natl Cancer Inst 84: 610–618.
[12]
Knudson AGJ (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68: 820–823.
[13]
Armitage P, Doll R (1954) The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer 8: 1–12.
[14]
Beerenwinkel N, Antal T, Dingli D, Traulsen A, Kinzler KW, et al. (2007) Genetic progression and the waiting time to cancer. PLoS Comput Biol 3: e225.
[15]
Durrett R, Schmidt D, Schweinsberg J (2009) A waiting time problem arising from the study of multi-stage carcinogenesis. Ann Appl Probab 19: 676–718.
[16]
Bozic I, Antal T, Ohtsuki H, Carter H, Kim D, et al. (2010) Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci U S A 107: 18545–18550.
[17]
Yachida S, Jones S, Bozic I, Antal T, Leary R, et al. (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114–1117.
[18]
Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, et al. (2008) Accurate whole human genome sequencing using reversible terminator chemistry. Nature 456: 53–59.
[19]
Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61: 759–767.
[20]
Sj？blom T, Jones S, Wood LD, Parsons DW, Lin J, et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314: 268–274.
[21]
Beerenwinkel N, Rahnenführer J, D？umer M, Hoffmann D, Kaiser R, et al. (2005) Learning multiple evolutionary pathways from cross-sectional data. J Comput Biol 12: 584–598.
[22]
Desper R, Jiang F, Kallioniemi OP, Moch H, Papadimitriou CH, et al. (2000) Distance-based reconstruction of tree models for oncogenesis. J Comput Biol 7: 789–803.
[23]
Desper R, Jiang F, Kallioniemi OP, Moch H, Papadimitriou CH, et al. (1999) Inferring tree models for oncogenesis from comparative genome hybridization data. J Comput Biol 6: 37–51.
[24]
Radmacher MD, Simon R, Desper R, Taetle R, Schaffer AA, et al. (2001) Graph models of oncogenesis with an application to melanoma. J Theor Biol 212: 535–548.
[25]
Rahnenführer J, Beerenwinkel N, Schulz WA, Hartmann C, von Deimling A, et al. (2005) Estimating cancer survival and clinical outcome based on genetic tumor progression scores. Bioinformatics 21: 2438–2446.
[26]
Attolini CS-O, Cheng Y-K, Beroukhim R, Getz G, Abdel-Wahab O, et al. (2010) A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proc Natl Acad Sci U S A 107: 17604–17609.
[27]
Beerenwinkel N, Eriksson N, Sturmfels B (2007) Conjunctive Bayesian networks. Bernoulli 13: 893–909.
[28]
Beerenwinkel N, Eriksson N, Sturmfels B (2006) Evolution on distributive lattices. J Theor Biol 242: 409–420.
[29]
Beerenwinkel N, Sullivant S (2009) Markov models for accumulating mutations. Biometrika 96: 645–661.
[30]
Gerstung M, Baudis M, Moch H, Beerenwinkel N (2009) Quantifying cancer progression with conjunctive Bayesian networks. Bioinformatics 25: 2809–2815.
[31]
Gerstung M, Beerenwinkel N (2010) Waiting Time Models of Cancer Progression. Mathematical Population Studies: An International Journal of Mathematical Demography 17: 115–135.
[32]
Laurent-Puig P, Blons H, Cugnenc PH (1999) Sequence of molecular genetic events in colorectal tumorigenesis. Eur J Cancer Prev 8: Suppl 1S39–47.
[33]
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al. (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765–773.
[34]
Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, et al. (1990) p53 gene mutations occur in combination with 17 p allelic deletions as late events in colorectal tumorigenesis. Cancer research 50: 7717.
[35]
Meza R, Jeon J, Moolgavkar SH, Luebeck EG (2008) Age-specific incidence of cancer: Phases, transitions, and biological implications. Proc Natl Acad Sci U S A 105: 16284–16289.
[36]
Morin PJ, Vogelstein B, Kinzler KW (1996) Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci U S A 93: 7950–7954.
[37]
Jones S, Chen W-D, Parmigiani G, Diehl F, Beerenwinkel N, et al. (2008) Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A 105: 4283–4288.
